Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases

Oncotarget

Volumn 6, Issue 33, 2015, Pages 34774-34787

  Leoni, Valerio ^a   Gatta, Valentina ^a   Palladini, Arianna ^a   Nicoletti, Giordano ^a   Ranieri, Dario ^a   Dall'Ora, Massimiliano ^a   Grosso, Valentina ^a   Rossi, Martina ^a   Alviano, Francesco ^a   Bonsi, Laura ^a   Nanni, Patrizia ^a   Lollini, Pier Luigi ^a   Campadelli Fiume, Gabriella ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Mesenchymal stem cells; Metastases; Oncolytic herpes simplex virus; Systemic delivery; Viral retargeting

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; BRAIN PROTECTION; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; EX VIVO STUDY; FEMALE; FETUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SYSTEMIC THERAPY; ANIMAL; BRAIN TUMOR; BREAST TUMOR; DRUG SCREENING; FLOW CYTOMETRY; LUNG TUMOR; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; NEOPLASM METASTASIS; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; PROCEDURES; SECONDARY; SIMPLEXVIRUS; VIROLOGY;

ANIMALS; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, NUDE; NEOPLASM METASTASIS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; SIMPLEXVIRUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946593779     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5793     Document Type: Article

References (56)

1. Cattaneo R, Miest T, Shashkova EV and Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol. 2008; 6:529-540.
2. Russell SJ, Peng KW and Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012; 30:658-670.
3. Miest TS and Cattaneo R. New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol. 2014; 12:23-34.
4. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33:2780-2788.
5. Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN, Whitley RJ and Gillespie GY. Phase Ib trial of mutant herpes simplex virus G207 inoculated preand post-tumor resection for recurrent GBM. Mol Ther. 2009; 17:199-207.
6. Cripe TP, Ngo MC, Geller JI, Louis CU, Currier MA, Racadio JM, Towbin AJ, Rooney CM, Pelusio A, Moon A, Hwang TH, Burke JM, Bell JC, Kirn DH and Breitbach CJ. Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients. Mol Ther. 2014.
7. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013; 19:329-336.
8. Russell SJ, Federspiel MJ, Peng KW, Tong C, Dingli D, Morice WG, Lowe V, O'Connor MK, Kyle RA, Leung N, Buadi FK, Rajkumar SV, Gertz MA, Lacy MQ and Dispenzieri A. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc. 2014; 89:926-933.
9. Campadelli-Fiume G, De Giovanni C, Gatta V, Nanni P, Lollini PL and Menotti L. Rethinking herpes simplex virus: the way to oncolytic agents. Rev Med Virol. 2011; 21:213-226.
10. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P, Love CA and Coffin RS. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003; 10:292-303.
11. Varghese S, Rabkin SD, Nielsen GP, MacGarvey U, Liu R and Martuza RL. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res. 2007; 67:9371-9379.
12. Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, Martuza RL and Rabkin SD. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci USA. 2013; 110:12006-12011.
13. Markert JM, Cody JJ, Parker JN, Coleman JM, Price KH, Kern ER, Quenelle DC, Lakeman AD, Schoeb TR, Palmer CA, Cartner SC, Gillespie GY and Whitley RJ. Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J Virol. 2012; 86:5304-5313.
14. Zhou G and Roizman B. Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor. Proc Natl Acad Sci USA. 2006; 103:5508-5513.
15. Zhou G, Ye GJ, Debinski W and Roizman B. Engineered herpes simplex virus 1 is dependent on IL13Ralpha2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci USA. 2002; 99:15124-15129.
16. Menotti L, Cerretani A, Hengel H and Campadelli-Fiume G. Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J Virol. 2008; 20(October):10153-10161.
17. Menotti L, Cerretani A and Campadelli-Fiume G. (2006). A HSV recombinant exhibiting a single chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors. The 31st International Herpesvirus Workshop. Seattle, USA.
18. Lollini PL, Menotti L, De Giovanni C, Campadelli-Fiume G and Nanni P. Oncolytic herpes virus retargeted to HER-2. Cell Cycle. 2009; 8:2859-2860.
19. Gambini E, Reisoli E, Appolloni I, Gatta V, CampadelliFiume G, Menotti L and Malatesta P. Replicationcompetent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma. Mol Ther. 2012; 20:994-1001.
20. Reisoli E, Gambini E, Appolloni I, Gatta V, Barilari M, Menotti L and Malatesta P. Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice. Cancer Gene Ther. 2012; 19:788-795.
21. Menotti L, Nicoletti G, Gatta V, Croci S, Landuzzi L, De Giovanni C, Nanni P, Lollini PL and Campadelli-Fiume G. Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proc Natl Acad Sci USA. 2009; 106:9039-9044.
22. Nanni P, Gatta V, Menotti L, De Giovanni C, Ianzano M, Palladini A, Grosso V, Dall'ora M, Croci S, Nicoletti G, Landuzzi L, Iezzi M, Campadelli-Fiume G and Lollini PL. Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus. PLoS Pathog. 2013; 9:e1003155.
23. Fu X and Zhang X. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res. 2002; 62:2306-2312.
24. Kulu Y, Dorfman JD, Kuruppu D, Fuchs BC, Goodwin JM, Fujii T, Kuroda T, Lanuti M and Tanabe KK. Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice. Cancer Gene Ther. 2009; 16:291-297.
25. Wang J, Hu P, Zeng M, Rabkin SD and Liu R. Oncolytic herpes simplex virus treatment of metastatic breast cancer. Int J Oncol. 2012; 40:757-763.
26. Kemeny N, Brown K, Covey A, Kim T, Bhargava A, Brody L, Guilfoyle B, Haag NP, Karrasch M, Glasschroeder B, Knoll A, Getrajdman G, Kowal KJ, Jarnagin WR and Fong Y. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther. 2006; 17:1214-1224.
27. Fong Y, Kim T, Bhargava A, Schwartz L, Brown K, Brody L, Covey A, Karrasch M, Getrajdman G, Mescheder A, Jarnagin W and Kemeny N. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther. 2009; 17:389-394.
28. Geevarghese SK, A. C, Geller DA, de Haan HA, Iagaru A, Knoll A, Nemunaitis J, Reid TR, Sze DY and Tanabe K. Phase II efficacy results using an oncolytic herpes simplex virus (NV1020) in patients with colorectal cancer metastatic to liver (mCRC). J Clin Oncol (ASCO Meeting Abstract). 2009; 27:4089.
29. Coffin RS. From virotherapy to oncolytic immunotherapy: where are we now? Curr Opin Virol. 2015; 13:93-100.
30. Russell SJ and Peng KW. The utility of cells as vehicles for oncolytic virus therapies. Curr Opin Mol Ther. 2008; 10:380-386.
31. Munguia A, Ota T, Miest T and Russell SJ. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther. 2008; 15:797-806.
32. Willmon C, Harrington K, Kottke T, Prestwich R, Melcher A and Vile R. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther. 2009; 17:1667-1676.
33. Coukos G, Makrigiannakis A, Kang EH, Caparelli D, Benjamin I, Kaiser LR, Rubin SC, Albelda SM and Molnar-Kimber KL. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res. 1999; 5:1523-1537.
34. Hammer K, Kazcorowski A, Liu L, Behr M, Schemmer P, Herr I and Nettelbeck DM. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells. Int J Cancer. 2015.
35. Ilett E, Kottke T, Donnelly O, Thompson J, Willmon C, Diaz R, Zaidi S, Coffey M, Selby P, Harrington K, Pandha H, Melcher A and Vile R. Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus. Mol Ther. 2014; 22:1851-1863.
36. Hsiao WC, Sung SY, Liao CH, Wu HC and Hsieh CL. Vitamin D3-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth. Mol Pharm. 2012; 9:1396-1408.
37. Castleton A, Dey A, Beaton B, Patel B, Aucher A, Davis DM and Fielding AK. Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. Blood. 2014; 123:1327-1335.
38. Duebgen M, Martinez-Quintanilla J, Tamura K, Hingtgen S, Redjal N, Wakimoto H and Shah K. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. J Natl Cancer Inst. 2014; 106:dju090.
39. Fujiwara S, Nawa A, Luo C, Kamakura M, Goshima F, Kondo C, Kiyono T, Kikkawa F and Nishiyama Y. Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer. Cancer Gene Ther. 2011; 18:77-86.
40. Nakashima H, Kaur B and Chiocca EA. Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev. 2010; 21:119-126.
41. Ventura C, Cantoni S, Bianchi F, Lionetti V, Cavallini C, Scarlata I, Foroni L, Maioli M, Bonsi L, Alviano F, Fossati V, Bagnara GP, Pasquinelli G, Recchia FA and Perbellini A. Hyaluronan mixed esters of butyric and retinoic Acid drive cardiac and endothelial fate in term placenta human mesenchymal stem cells and enhance cardiac repair in infarcted rat hearts. J Biol Chem. 2007; 282:14243-14252.
42. Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz AJ, March KL, Redl H, Rubin JP, Yoshimura K and Gimble JM. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy. 2013; 15:641-648.
43. Pierdomenico L, Bonsi L, Calvitti M, Rondelli D, Arpinati M, Chirumbolo G, Becchetti E, Marchionni C, Alviano F, Fossati V, Staffolani N, Franchina M, Grossi A and Bagnara GP. Multipotent mesenchymal stem cells with immunosuppressive activity can be easily isolated from dental pulp. Transplantation. 2005; 80:836-842.
44. Cocchi F, Menotti L, Mirandola P, Lopez M and Campadelli-Fiume G. The ectodomain of a novel member of the immunoglobulin subfamily related to the poliovirus receptor has the attributes of a bona fide receptor for herpes simplex virus types 1 and 2 in human cells. J Virol. 1998; 72:9992-10002.
45. Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU and Shapiro CL. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Annals of Oncology: ESMO. 2013; 24:1526-1533.
46. Office of New Drugs C, FDA. (2005). Guidance for Industry. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. In: U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER) ed.
47. Mader EK, Butler G, Dowdy SC, Mariani A, Knutson KL, Federspiel MJ, Russell SJ, Galanis E, Dietz AB and Peng KW. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med. 2013; 11:20.
48. Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH and Bang OY. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010; 28:1099-1106.
49. De Giovanni C, Nicoletti G, Quaglino E, Landuzzi L, Palladini A, Ianzano ML, Dall'Ora M, Grosso V, Ranieri D, Laranga R, Croci S, Amici A, Penichet ML, Iezzi M, Cavallo F, Nanni P, et al. Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. Breast cancer research: 2014; 16:R10.
50. Moasser MM and Krop IE. The Evolving Landscape of HER2 Targeting in Breast Cancer. JAMA oncology. 2015.
51. Zhao Q, Gregory CA, Lee RH, Reger RL, Qin L, Hai B, Park MS, Yoon N, Clough B, McNeill E, Prockop DJ and Liu F. MSCs derived from iPSCs with a modified protocol are tumor-tropic but have much less potential to promote tumors than bone marrow MSCs. Proc Natl Acad Sci USA. 2015; 112:530-535.
52. Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Ianzano ML, Grosso V, Stivani V, Antognoli A, Lamolinara A, Landuzzi L, di Tomaso E, Iezzi M, De Giovanni C and Lollini PL. Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/-mice and treatment with PI3K inhibitor. PLoS One. 2012; 7:e39626.
53. Sarmiento M, Haffey M and Spear PG. Membrane proteins specified by herpes simplex viruses. III. Role of glycoprotein VP7(B2) in virion infectivity. J Virol. 1979; 29:1149-1158.
54. Pereira L, Dondero DV, Gallo D, Devlin V and Woodie JD. Serological analysis of herpes simplex virus types 1 and 2 with monoclonal antibodies. Infect Immun. 1982; 35:363-367.
55. Nanni P, Nicoletti G, Landuzzi L, Croci S, Murgo A, Palladini A, Antognoli A, Ianzano ML, Stivani V, Grosso V, Maira SM, Garcia-Echeverria C, Scotlandi K, De Giovanni C and Lollini PL. High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy. Eur J Cancer. 2010; 46:659-668.
56. Song P, Xie Z, Guo L, Wang C, Xie W and Wu Y. Human genome-specific real-time PCR method for sensitive detection and reproducible quantitation of human cells in mice. Stem Cell Rev. 2012; 8:1155-1162.